Literature DB >> 16623656

Epileptogenic drugs: a systematic review.

Claudio Ruffmann1, Graziella Bogliun, Ettore Beghi.   

Abstract

A wide range of substances, including drugs and illicit compounds, increase the risk of epileptic seizures. In this systematic review, the authors address the issue of the epileptogenic potential of marketed drugs, with the aims of providing criteria for the assessment of the cause-effect relationship between drug exposure and the risk of seizures; and to identify the compounds better fulfilling the requirements of an epileptogenic drug. Finding a correlation between drug exposure and occurrence of seizures does not necessarily establish a causal association. In light of the available evidence, even with these limitations, some conclusive remarks can be made on the epileptogenic potential of some active principles. Drugs with high epileptogenic potential include meperidine, sevoflurane, clozapine, phenothiazines and cyclosporine. Drugs with intermediate epileptogenic potential include propofol, maprotiline, tricyclic antidepressants and chlorambucil. Drugs with low epileptogenic potential include fluorquinolones, carbapenems, bupropion and iodinated contrast media. Drugs with minimal or inconclusive epileptogenic potential include interferon alpha.

Entities:  

Mesh:

Year:  2006        PMID: 16623656     DOI: 10.1586/14737175.6.4.575

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  13 in total

1.  Rapamycin attenuates aggressive behavior in a rat model of pilocarpine-induced epilepsy.

Authors:  X Huang; J McMahon; Y Huang
Journal:  Neuroscience       Date:  2012-04-20       Impact factor: 3.590

Review 2.  Medically serious adverse effects of newer antidepressants.

Authors:  Rajnish Mago; Rajeev Mahajan; Michael E Thase
Journal:  Curr Psychiatry Rep       Date:  2008-06       Impact factor: 5.285

3.  Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.

Authors:  Christoph U Correll; Johan Detraux; Jan De Lepeleire; Marc De Hert
Journal:  World Psychiatry       Date:  2015-06       Impact factor: 49.548

4.  Contrast Media Adverse Drug Reactions in Highly Polluted Environment.

Authors:  Natalia Sauer; Wojciech Szlasa; Laura Jonderko; Krystyna Głowacka; Katarzyna Karłowicz-Bodalska; Anna Wiela-Hojeńska
Journal:  Int J Environ Res Public Health       Date:  2022-06-09       Impact factor: 4.614

5.  Pharmacological characterization of GABAA receptors in taurine-fed mice.

Authors:  William J L'Amoreaux; Alexandra Marsillo; Abdeslem El Idrissi
Journal:  J Biomed Sci       Date:  2010-08-24       Impact factor: 8.410

6.  Lifestyle factors, psychiatric and neurologic comorbidities, and drug use associated with incident seizures among adult patients with depression: a population-based nested case-control study.

Authors:  Marlene Bloechliger; Alessandro Ceschi; Stephan Rüegg; Susan Sara Jick; Christoph Rudolf Meier; Michael Bodmer
Journal:  Eur J Epidemiol       Date:  2016-05-04       Impact factor: 8.082

7.  Antipsychotic drug use and the risk of seizures: follow-up study with a nested case-control analysis.

Authors:  Marlene Bloechliger; Stephan Rüegg; Susan S Jick; Christoph R Meier; Michael Bodmer
Journal:  CNS Drugs       Date:  2015-07       Impact factor: 5.749

Review 8.  The Impact of Psychoactive Drugs on Seizures and Antiepileptic Drugs.

Authors:  Mitra Habibi; Felecia Hart; Jacquelyn Bainbridge
Journal:  Curr Neurol Neurosci Rep       Date:  2016-08       Impact factor: 5.081

9.  Presentation and management of community-onset vs hospital-onset first seizures.

Authors:  Emma Foster; Sarah Holper; Zhibin Chen; Patrick Kwan
Journal:  Neurol Clin Pract       Date:  2018-10

10.  Meperidine induced seizure in a patient with lyme borreliosis.

Authors:  Hatice Evren Eker; Hatice Izmirli; Sule Akin; Nesrin Bozdogan Ozyilkan; Anis Aribogan; Gulnaz Arslan
Journal:  J Clin Med Res       Date:  2009-12-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.